Emory Coleman
Primary Care · Huntsville, ALNPI 1093314890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 33.7% of the total. Reporting peaked in 2021 at $1,279 and has fallen 98.3% since, to $21 in 2025.
Across 227 payments — averaging $12.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$993
- Boehringer Ingelheim$547
- Takeda Pharmaceuticals U.S.A., Inc.$419
- Lilly USA, LLC$208
- Amgen$168
- Biohaven Pharmaceutical Holding Company Ltd.$131
- plus $479 from 16 others
What the payments were for
- Food & beverage$2,82096%
- Education$1254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 115 | $993 |
| Boehringer Ingelheim | 40 | $547 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $419 |
| Lilly USA, LLC | 13 | $208 |
| Amgen | 8 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $131 |
| AbbVie | 4 | $63 |
| Pfizer | 3 | $58 |
| GSK | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 4 | $49 |
| AstraZeneca | 3 | $48 |
| Novartis | 1 | $30 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Abbott | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Intra-sana Laboratories | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Vistapharm, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$114
How this compares
$2,945 in reported general payments places this provider in the 75th percentile of 159 primary care providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 17 | $283 |
| Atorvastatin Calcium | 21 | $164 |
| Amlodipine Besylate | 15 | $143 |
| Omeprazole | 17 | $120 |
Paid to pharmacies, not to this prescriber.
Other primary care in Huntsville
- Cleo ValdezHuntsville$14K
- Christine WoodHuntsville$5K
- Allison BrownHuntsville$4K
- Meredith PolsHuntsville$3K
- Alyson JusticeHuntsville$2K
- Emily KomaraHuntsville$2K
- Johnnie AmadiHuntsville$2K
- Keith MatthewsOpelika$20K
- Troy HendersonFultondale$18K
- April TateDothan$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.